Ionis Pharmaceuticals (IONS) CEO sells shares, exercises stock options

Rhea-AI Filing Summary

Ionis Pharmaceuticals CEO Brett P. Monia reported a series of option exercises paired with open-market sales of common stock. Over June 24–26, 2026, he exercised options covering 85,637 shares and sold the same number of shares in the market, a net disposition.

Sales included 50,000 shares at a weighted average price of $80.59, 21,072 shares at $78.49, and 14,565 shares at $78.4128. The filing states these sales were made pursuant to a Rule 10b5-1 Trading Plan. After the transactions, he directly holds 245,571 shares of common stock and 99,872 non-qualified stock options.

Insights

Insider trading analyst

CEO executes pre-planned exercise-and-sell, retains sizable stake.

Brett P. Monia, CEO of Ionis Pharmaceuticals, exercised options for 85,637 shares and sold an equal number of shares over June 24–26, 2026. This is a classic exercise-and-sell pattern, converting option value into cash while realizing gains above strike prices of $32.60 and $56.78.

The filing notes sales were made under a Rule 10b5-1 Trading Plan adopted on December 8, 2025, indicating these trades were pre-scheduled rather than opportunistic. After the transactions, Monia still directly owns 245,571 common shares plus 99,872 non-qualified stock options, so he maintains substantial exposure to Ionis equity.

Because the trades are pre-planned and the CEO retains a significant position, this activity appears routine from a governance perspective. Future company filings may provide additional context if his ownership level changes meaningfully, but based on this report alone, the information is largely administrative.

Insider Trade Summary 10b5-1

Net Seller: 85,637 shares ($6,825,524)

Net Sell 9 txns

Insider Monia Brett P

Role Chief Executive Officer

Sold 85,637 shs ($6.83M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	50,000	$0.00	--
Exercise	Common Stock	50,000	$56.78	$2.84M
Sale	Common Stock	50,000	$80.59	$4.03M
Exercise	Non-Qualified Stock Option (right to buy)	21,072	$0.00	--
Exercise	Common Stock	21,072	$32.60	$687K
Sale	Common Stock	21,072	$78.49	$1.65M
Exercise	Non-Qualified Stock Option (right to buy)	14,565	$0.00	--
Exercise	Common Stock	14,565	$32.60	$475K
Sale	Common Stock	14,565	$78.4128	$1.14M

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 99,872 shares (Direct, null); Common Stock — 295,571 shares (Direct, null)

Footnotes (1)

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.87 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.005 to $78.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80 to $81 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

Key Figures

Shares sold June 26, 2026: 50,000 shares at $80.59 Shares sold June 25, 2026: 21,072 shares at $78.49 Shares sold June 24, 2026: 14,565 shares at $78.4128 +4 more

7 metrics

Shares sold June 26, 2026 50,000 shares at $80.59 Open-market sale of common stock

Shares sold June 25, 2026 21,072 shares at $78.49 Open-market sale of common stock

Shares sold June 24, 2026 14,565 shares at $78.4128 Open-market sale of common stock

Options exercised 85,637 shares Derivative exercises at $32.60 and $56.78

Common shares after transactions 245,571 shares Direct ownership of Ionis common stock

Options remaining 99,872 options Non-qualified stock options outstanding

Net shares sold 85,637 shares Net-sell direction per transaction summary

Key Terms

Rule 10b5-1 Trading Plan, Non-Qualified Stock Option (right to buy), weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1 Trading Plan regulatory

"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Non-Qualified Stock Option (right to buy) financial

"security_title: Non-Qualified Stock Option (right to buy)"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 07:10 PM Accepted by SEC EDGAR 06/26/2026 - 07:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monia Brett P

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/24/2026		M		14,565	A	$32.6	260,136	D
Common Stock	06/24/2026		S		14,565(1)	D	$78.4128(2)	245,571	D
Common Stock	06/25/2026		M		21,072	A	$32.6	266,643	D
Common Stock	06/25/2026		S		21,072(1)	D	$78.49(3)	245,571	D
Common Stock	06/26/2026		M		50,000	A	$56.78	295,571	D
Common Stock	06/26/2026		S		50,000(1)	D	$80.59(4)	245,571	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$32.6	06/24/2026		M			14,565	01/03/2023	01/02/2032	Common Stock	14,565	$0.0	21,072	D
Non-Qualified Stock Option (right to buy)	$32.6	06/25/2026		M			21,072	01/03/2023	01/02/2032	Common Stock	21,072	$0.0	0	D
Non-Qualified Stock Option (right to buy)	$56.78	06/26/2026		M			50,000	01/04/2022	01/03/2028	Common Stock	50,000	$0.0	99,872	D

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.87 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.005 to $78.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80 to $81 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Ionis (IONS) CEO Brett Monia report?

Ionis CEO Brett Monia reported exercising stock options and selling common shares. Over June 24–26, 2026, he exercised options for 85,637 shares and sold the same number in open-market transactions, converting option holdings into common stock and then into cash.

How many Ionis (IONS) shares did the CEO sell in this Form 4?

The CEO sold a total of 85,637 Ionis common shares. This included 14,565 shares on June 24, 21,072 shares on June 25, and 50,000 shares on June 26, 2026, at weighted average prices around the high-$70 to low-$80 range.

Were the Ionis (IONS) CEO share sales made under a Rule 10b5-1 plan?

Yes. The filing states the shares were sold pursuant to a Rule 10b5-1 Trading Plan adopted on December 8, 2025. Such plans pre-schedule transactions, indicating the sales’ timing was set in advance rather than based on short-term market developments.

How many Ionis (IONS) shares and options does the CEO own after these trades?

After the reported transactions, the CEO directly holds 245,571 shares of Ionis common stock. He also holds 99,872 non-qualified stock options, giving him additional potential future ownership if those options are exercised before their expiration dates.

What prices were involved in the Ionis (IONS) CEO’s option exercises and share sales?

Exercised options had conversion prices of $32.60 and $56.78 per share. The resulting common shares were sold at weighted average prices of $78.4128, $78.49, and $80.59, with detailed price ranges disclosed for each sale date in the Form 4 footnotes.

Does the Ionis (IONS) CEO’s Form 4 indicate ongoing option holdings?

Yes. The Form 4 shows that after exercising 85,637 options, the CEO still holds 99,872 non-qualified stock options. These options, with specified exercise and expiration dates, represent additional potential future ownership beyond his current common share holdings.